Novartis And Drugs For Neglected Diseases Initiative (DNDi) to Collaborate On The Development Of a New Oral Drug to Treat Visceral Leishmaniasis

Must Read

List of Guaranty Trust Bank Sort Codes & Branches (with addresses) in Nigeria

The sort code is a number that usually identifies both the bank and the branch where an account is...

Top 10 Most Expensive Universities In Nigeria

For many Nigerians, high-quality higher education is a luxury. There are many private universities who are known not only...

List of Access Bank Sort Codes & Branches (with addresses) in Nigeria

The sort code is a number which usually identifies both the bank and the branch where an account is...
Novartis And Drugs For Neglected Diseases Initiative (DNDi) to Collaborate On The Development Of a New Oral Drug to Treat Visceral LeishmaniasisNovartis And Drugs For Neglected Diseases Initiative (DNDi) to Collaborate On The Development Of a New Oral Drug to Treat Visceral Leishmaniasis

LXE408 is a first-in-class compound, discovered at Novartis with financial support from the Wellcome Trust; Novartis is responsible for completing Phase I clinical trials and has committed to maximizing access in endemic countries, once approved; DNDi will lead Phase II and III clinical development, starting in India with additional trials planned in East Africa; Leishmaniasis, which is transmitted by the sandfly, affects over one billion people; visceral leishmaniasis, the most serious form of the disease, affects an estimated 50 000 to 90 000 people per year.

Novartis and the Drugs for Neglected Diseases initiative (DNDi)a not-for-profit research and development (R&D) organization, have signed a collaboration and licence agreement to jointly develop LXE408, as a potential new oral treatment for visceral leishmaniasis, one of the world’s leading parasitic killers.

LXE408 is a first-in-class compound, discovered at Novartis with financial support from the Wellcome Trust. Within the scope of the agreement, Novartis is responsible for completing Phase I clinical trials. In addition, it will drive pharmaceutical development and regulatory submissions. Upon approval, Novartis has committed to distributing the drug on an affordable basis worldwide with a focus on maximizing access in endemic countries.

DNDwill lead Phase II and Phase III clinical development, with the first Phase II study scheduled to start in early 2021 in India. Additional trials are planned to take place in East Africa, which has the highest burden of visceral leishmaniasis.

- Advertisement -

Existing treatments for visceral leishmaniasis are simply not good enough. They are too long, increasingly ineffective, and can be toxic, painful, and costly,” said Dr Bernard Pécoul, Executive Director of DNDi.Our hope is to radically transform this by developing new oral drugs that are affordable, safe, effective, easy to take, and can also be adapted to meet the treatment needs of patients in different countries.”

Over one billion people worldwide are at risk of leishmaniasis, which is transmitted by the bite of a sandfly. Visceral leishmaniasis, also known as kala-azar, is the most serious form of leishmaniasis, causing fever, weight loss, spleen and liver enlargement, and if left untreated, death. There are an estimated 50 000 to 90 000 new cases per year. Treating the disease is complex as it is dependent on the species of infecting parasite and the country, as treatment responses differ from region to region.

Novartis has a long-term commitment to neglected tropical diseases that spans several decades. Diseases caused by kinetoplastid parasites, such as leishmaniasis, are one of our strategic research priorities and, together with our partners, we have developed a promising portfolio of drug candidates,” said Dr Lutz Hegemann, Chief Operating Officer for Global Health at Novartis.We are excited to collaborate with DNDi to reimagine treatment options for people with leishmaniasis around the world.”

Broader partnerships
The collaboration between DNDand Novartis is aligned with a broader program with Wellcome and other partners to develop new combinations of entirely new, all-orally acting chemical entities, to treat visceral leishmaniasis and cutaneous leishmaniasis, another form of the disease.

- Advertisement -
Read:  Chinese Firm Plans Computer Plant in Nigeria

The program brings together a strong consortium of R&D partners, including the University of Dundee, GSK, Pfizer, TB Alliance, and Takeda Pharmaceutical Company Limited. These partners have built a portfolio of lead series, pre-clinical and clinical drug candidates, originating from different chemical classes with different mechanisms of action against leishmania parasites. 

We are delighted to be partnering with Novartis from drug development to delivering a promising new oral treatment for visceral leishmaniasis. Together, we can contribute to sustaining elimination efforts in India and altering the treatment landscape in East Africa,” said Dr Fabiana Alves, Head of Visceral Leishmaniasis Clinical Program at DNDi.

- Advertisement -

Subscribe to BrandSpur Ng

Subscribe for latest updates. Signup to best of brands and business news, informed analysis and opinions among others that can propel you, your business or brand to greater heights.

Latest News

Singapore Start-Ups ‘Up’ by BetterTradeOff and digital wealth manager Syfe Partner to Provide Peace of Mind Amid Uncertain Times

SINGAPORE - Media OutReach - 2 April 2020 - Two Singapore-based start-ups, life planning platform 'Up' by BetterTradeOff (www.upplan.sg) and digital wealth...

CPA Australia: 44 Per Cent of Small Businesses in Hong Kong Sought External Funds for Survival Before Covid-19 Pandemic

HONG KONG, CHINA - Media OutReach - 2 April 2020 - The 11th APAC Small Business Survey conducted by CPA Australia reveals that 44 per cent of...

Nestlé Recognized For Higher Animal Welfare Standards

The 2019 Business Benchmark on Farm Animal Welfare (BBFAW) today recognized Nestlé’s efforts to enhance animal welfare (pdf, 2Mb) throughout its supply chain. For the first...

Mouka Donates 200 Mattresses to Ogun State Government For COVID-19 Isolation Centres

Mouka, Nigeria’s leading brand of mattresses and bedding products, has donated 200 mattresses to Ogun State Government for the enhancement of isolation centres used...

Golden Penny Donates Food Products Across The Country

Flour Mills of Nigeria Plc, Nigeria’s leading integrated food business and agro-allied Group, owners of the iconic food brand, Golden Penny has announced its...
- Advertisement -
BrandsPur Weekly Cartoons
%d bloggers like this: